vs
豪洛捷（HOLX）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Rollins, Inc.的1.2倍（$1.0B vs $906.4M），豪洛捷净利率更高（17.1% vs 11.9%，领先5.2%），Rollins, Inc.同比增速更快（10.2% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $111.2M），过去两年豪洛捷的营收复合增速更高（1.5% vs 0.8%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
HOLX vs ROL — 直观对比
营收规模更大
HOLX
是对方的1.2倍
$906.4M
营收增速更快
ROL
高出7.7%
2.5%
净利率更高
HOLX
高出5.2%
11.9%
自由现金流更多
HOLX
多$104.0M
$111.2M
两年增速更快
HOLX
近两年复合增速
0.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $906.4M |
| 净利润 | $179.1M | $107.8M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | 16.1% |
| 净利率 | 17.1% | 11.9% |
| 营收同比 | 2.5% | 10.2% |
| 净利润同比 | -10.9% | 2.5% |
| 每股收益（稀释后） | $0.79 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.0B | $912.9M | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $999.5M | ||
| Q1 25 | $1.0B | $822.5M | ||
| Q4 24 | $1.0B | $832.2M | ||
| Q3 24 | $988.0M | $916.3M | ||
| Q2 24 | $1.0B | $891.9M |
净利润HOLXROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $179.1M | $116.4M | ||
| Q3 25 | $187.2M | $163.5M | ||
| Q2 25 | $194.9M | $141.5M | ||
| Q1 25 | $-17.4M | $105.2M | ||
| Q4 24 | $201.0M | $105.7M | ||
| Q3 24 | $178.6M | $136.9M | ||
| Q2 24 | $194.5M | $129.4M |
毛利率HOLXROL
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
营业利润率HOLXROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 22.6% | 17.5% | ||
| Q3 25 | 22.6% | 21.9% | ||
| Q2 25 | 24.9% | 19.8% | ||
| Q1 25 | -0.7% | 17.3% | ||
| Q4 24 | 22.5% | 18.1% | ||
| Q3 24 | 23.3% | 20.9% | ||
| Q2 24 | 24.1% | 20.4% |
净利率HOLXROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | 17.1% | 12.8% | ||
| Q3 25 | 17.8% | 15.9% | ||
| Q2 25 | 19.0% | 14.2% | ||
| Q1 25 | -1.7% | 12.8% | ||
| Q4 24 | 19.7% | 12.7% | ||
| Q3 24 | 18.1% | 14.9% | ||
| Q2 24 | 19.2% | 14.5% |
每股收益（稀释后）HOLXROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $0.79 | $0.24 | ||
| Q3 25 | $0.84 | $0.34 | ||
| Q2 25 | $0.86 | $0.29 | ||
| Q1 25 | $-0.08 | $0.22 | ||
| Q4 24 | $0.87 | $0.22 | ||
| Q3 24 | $0.75 | $0.28 | ||
| Q2 24 | $0.82 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $116.5M |
| 总债务越低越好 | $2.5B | $650.6M |
| 股东权益账面价值 | $5.2B | $1.4B |
| 总资产 | $9.2B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资HOLXROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $2.4B | $100.0M | ||
| Q3 25 | $2.2B | $127.4M | ||
| Q2 25 | $1.9B | $123.0M | ||
| Q1 25 | $1.6B | $201.2M | ||
| Q4 24 | $2.0B | $89.6M | ||
| Q3 24 | $2.3B | $95.3M | ||
| Q2 24 | $2.4B | $106.7M |
总债务HOLXROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $2.5B | $486.1M | ||
| Q3 25 | $2.5B | $485.7M | ||
| Q2 25 | $2.5B | $485.3M | ||
| Q1 25 | $2.5B | $485.5M | ||
| Q4 24 | $2.5B | $395.3M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
股东权益HOLXROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $5.2B | $1.4B | ||
| Q3 25 | $5.0B | $1.5B | ||
| Q2 25 | $4.8B | $1.4B | ||
| Q1 25 | $4.6B | $1.4B | ||
| Q4 24 | $4.8B | $1.3B | ||
| Q3 24 | $5.1B | $1.3B | ||
| Q2 24 | $5.0B | $1.2B |
总资产HOLXROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $9.2B | $3.1B | ||
| Q3 25 | $9.0B | $3.2B | ||
| Q2 25 | $8.8B | $3.2B | ||
| Q1 25 | $8.5B | $2.9B | ||
| Q4 24 | $8.7B | $2.8B | ||
| Q3 24 | $9.2B | $2.8B | ||
| Q2 24 | $8.9B | $2.8B |
负债/权益比HOLXROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.48× | 0.35× | ||
| Q3 25 | 0.50× | 0.32× | ||
| Q2 25 | 0.52× | 0.34× | ||
| Q1 25 | 0.55× | 0.36× | ||
| Q4 24 | 0.53× | 0.30× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $111.2M |
| 自由现金流率自由现金流/营收 | 20.5% | 12.3% |
| 资本支出强度资本支出/营收 | 1.4% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.28× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $621.1M |
8季度趋势，按日历期对齐
经营现金流HOLXROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $229.9M | $164.7M | ||
| Q3 25 | $355.1M | $191.3M | ||
| Q2 25 | $343.3M | $175.1M | ||
| Q1 25 | $169.4M | $146.9M | ||
| Q4 24 | $189.3M | $188.2M | ||
| Q3 24 | $367.0M | $146.9M | ||
| Q2 24 | $405.8M | $145.1M |
自由现金流HOLXROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $215.2M | $159.0M | ||
| Q3 25 | $341.4M | $182.8M | ||
| Q2 25 | $330.5M | $168.0M | ||
| Q1 25 | $153.9M | $140.1M | ||
| Q4 24 | $172.5M | $184.0M | ||
| Q3 24 | $350.6M | $139.4M | ||
| Q2 24 | $385.3M | $136.4M |
自由现金流率HOLXROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 20.5% | 17.4% | ||
| Q3 25 | 32.5% | 17.8% | ||
| Q2 25 | 32.3% | 16.8% | ||
| Q1 25 | 15.3% | 17.0% | ||
| Q4 24 | 16.9% | 22.1% | ||
| Q3 24 | 35.5% | 15.2% | ||
| Q2 24 | 38.1% | 15.3% |
资本支出强度HOLXROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 1.4% | 0.6% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 1.3% | 0.7% | ||
| Q1 25 | 1.5% | 0.8% | ||
| Q4 24 | 1.6% | 0.5% | ||
| Q3 24 | 1.7% | 0.8% | ||
| Q2 24 | 2.0% | 1.0% |
现金转化率HOLXROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 1.28× | 1.41× | ||
| Q3 25 | 1.90× | 1.17× | ||
| Q2 25 | 1.76× | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | 0.94× | 1.78× | ||
| Q3 24 | 2.05× | 1.07× | ||
| Q2 24 | 2.09× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ROL
暂无分部数据
